Belgium’s Cardio3, China’s Medisun Join Hands On Phase III Trials In U.S.
This article was originally published in PharmAsia News
Executive Summary
Belgium’s Cardio3 BioSciences secures 25 million euros from China’s Medisun International to aid clinical trial efforts in the United States on a heart failure treatment candidate.
You may also be interested in...
Cardio3 BioSciences’ Stem Cell Heart Therapy Phase III Trials Bolstered By New Funding
Belgian biotech Cardio3 BioSciences is in a leading position in the race to develop a stem cell-based therapy for severe heart failure.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.